PL3223807T3 - Metoda zapobiegania lub leczenia choroby lub stanu płuc - Google Patents

Metoda zapobiegania lub leczenia choroby lub stanu płuc

Info

Publication number
PL3223807T3
PL3223807T3 PL15862576T PL15862576T PL3223807T3 PL 3223807 T3 PL3223807 T3 PL 3223807T3 PL 15862576 T PL15862576 T PL 15862576T PL 15862576 T PL15862576 T PL 15862576T PL 3223807 T3 PL3223807 T3 PL 3223807T3
Authority
PL
Poland
Prior art keywords
treating
preventing
condition
pulmonary disease
pulmonary
Prior art date
Application number
PL15862576T
Other languages
English (en)
Inventor
Anantha HARIJITH
Viswanathan NATARAJAN
Roberto F. MACHADO
Jeffrey Jacobson
Original Assignee
The Board Of Trustees Of The University Of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Illinois filed Critical The Board Of Trustees Of The University Of Illinois
Publication of PL3223807T3 publication Critical patent/PL3223807T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15862576T 2014-11-24 2015-11-24 Metoda zapobiegania lub leczenia choroby lub stanu płuc PL3223807T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083693P 2014-11-24 2014-11-24
PCT/US2015/062332 WO2016085933A1 (en) 2014-11-24 2015-11-24 Method of preventing or treating a pulmonary disease or condition
EP15862576.4A EP3223807B1 (en) 2014-11-24 2015-11-24 Method of preventing or treating a pulmonary disease or condition

Publications (1)

Publication Number Publication Date
PL3223807T3 true PL3223807T3 (pl) 2022-01-03

Family

ID=56074949

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15862576T PL3223807T3 (pl) 2014-11-24 2015-11-24 Metoda zapobiegania lub leczenia choroby lub stanu płuc

Country Status (5)

Country Link
US (1) US11026918B2 (pl)
EP (1) EP3223807B1 (pl)
ES (1) ES2895850T3 (pl)
PL (1) PL3223807T3 (pl)
WO (1) WO2016085933A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325201B (zh) 2016-08-15 2026-03-27 儿童医学中心公司 ApoM-Fc融合蛋白、其与鞘氨醇1-磷酸(S1P)的复合物以及用于治疗血管和非血管疾病的方法
US10894960B2 (en) 2016-08-30 2021-01-19 Children's Hospital Medical Center Compositions and methods for nucleic acid transfer
US12411144B2 (en) * 2017-03-22 2025-09-09 Children's Hospital Medical Center Compositions and methods for treatment of lung function
EP3668551A4 (en) 2017-08-15 2021-04-14 Children's Medical Center Corporation APOM FC FUSION PROTEINS AND USES THEREOF
US12415847B2 (en) 2018-10-12 2025-09-16 Children's Medical Center Corporation ApoM-Fc fusion proteins for treating lung diseases
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US8324237B2 (en) 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
ES2528451T3 (es) 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
US20070032531A1 (en) * 2005-08-04 2007-02-08 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
US8372888B2 (en) 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
DE102008029734A1 (de) 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidinderivate
EP2384118A4 (en) * 2008-12-30 2012-01-11 Musc Found For Res Dev SPHINGOGUANIDINE AND ITS USE AS AN INHIBITOR OF SPHINGOSINKINASE
CA2808582A1 (en) 2009-08-14 2011-02-17 University Of Virginia Patent Foundation Imidamide sphingosine kinase inhibitors
CA2784647A1 (en) 2009-12-17 2011-07-14 Merck Patent Gmbh Inhibitors of sphingosine kinase
CN103703097A (zh) 2011-07-19 2014-04-02 日东电工株式会社 透明压敏粘合粘接剂和耐高温压敏粘合剂
US9688668B2 (en) 2012-02-08 2017-06-27 University Of Virginia Patent Foundation Long chain base sphingosine kinase inhibitors
US9206423B2 (en) 2012-12-30 2015-12-08 The Regents Of The University Of California Methods of modulating compliance of the trabecular meshwork
WO2014105770A1 (en) * 2012-12-31 2014-07-03 Scientific Design Company, Inc. Start-up process for high selectivity ethylene oxide catalysts
WO2014118556A2 (en) 2013-01-31 2014-08-07 Research Foundation Of The City University Of New York Selective inhibitors and allosteric activators of sphingosine kinase
WO2014157382A1 (ja) 2013-03-29 2014-10-02 味の素株式会社 スフィンゴシンキナーゼ阻害剤

Also Published As

Publication number Publication date
EP3223807B1 (en) 2021-09-15
WO2016085933A1 (en) 2016-06-02
EP3223807A1 (en) 2017-10-04
ES2895850T3 (es) 2022-02-22
US20170360749A1 (en) 2017-12-21
EP3223807A4 (en) 2018-08-01
US11026918B2 (en) 2021-06-08

Similar Documents

Publication Publication Date Title
LT3386511T (lt) Hantingtono ligos gydymo būdai
SG11201701723XA (en) Methods of treating liver disease
GB201701673D0 (en) Methods of well treatment
IL255423A0 (en) Methods for treating neurodegenerative disease
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
IL248856B (en) New treatment
GB201410116D0 (en) Method of treatment
PT3164394T (pt) Inibidores gls1 para o tratamento de doenças
GB201406538D0 (en) Method of treating a material
PL3220952T3 (pl) Sposób leczenia lub zapobiegania udarowi
BR112017004533A2 (pt) método para tratamento de sarcoidose pulmonar
IL256109A (en) Methods for the treatment or prevention of protopathy
PL3223807T3 (pl) Metoda zapobiegania lub leczenia choroby lub stanu płuc
SG10202008024VA (en) Method for Treating Heart Failure
SG10201912688YA (en) A method of treatment
IL253028A0 (en) treatment method
GB201402036D0 (en) Method for determination of the status of a disease
GB201416832D0 (en) Methods of treatment
GB201521886D0 (en) A method of treating a well
IL252904A0 (en) Methods and factors for treating diseases
SG11201609522TA (en) Methods for treating cardiovascular diseases
GB201406225D0 (en) Treatment for respiratory disease
GB2543449B (en) Method of completing a well
GB201421980D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment